Call Us: 1.800.873.5297

By

Pradaxa® MDL Lawsuit Update (MDL 2385): First Pradaxa® Trial Now Set to Begin September 2014

The first trial in the Pradaxa® Multidistrict Litigation entitled In re: Pradaxa® (Dabigatran Etexilate) Products Liability Litigation (MDL 2385, Case No. 12-md-2385) is set to begin this fall in the United States District Court for the Southern District of Illinois. According to a recent Case Management Order issued by The Honorable Chief Judge David R. Herndon, the first Pradaxa® trial has been set for September 15, 2014.

“The scheduling of the first Pradaxa® trial is of great interest to our firm, as we continue to hear from individuals who allegedly experienced life-threatening episodes of internal bleeding after using Pradaxa®,” says Roger C. Denton, Plaintiffs’ Co-Lead Counsel in the Pradaxa® MDL. Schlichter, Bogard & Denton, LLP are leaders in the national Pradaxa® Multidistrict Litigation (MDL 2385). The attorneys at Schlichter, Bogard & Denton, LLP are offering a free and confidential case review to those who allege to have been injured, or lost loved ones, after using Pradaxa®.

Pradaxa® is an oral anticoagulant (blood thinner) launched by Boehringer Ingelheim in October 2010. In December 2011, the U.S. Food and Drug Administration (FDA) issued a Safety Announcement that the FDA was evaluating post-marketing reports of serious – and even fatal – bleeding events in patients taking Pradaxa®. According to the Judicial Panel on Multidistrict Litigation, over 2,000 federal Pradaxa® lawsuits are currently pending against the drug’s manufacturers in the United States District Court for the Southern District of Illinois before the Honorable Chief Judge David R. Herndon, and the number of cases is expected to continue to grow. These individuals allege that they have suffered severe – and often fatal – injuries while using Pradaxa® and that Boehringer Ingelheim failed to adequately warn about bleeding risks and the lack of a reversal agent.

Previously on February 7, 2014, The New York Times reported that numerous documents had been made public in the Pradaxa® Multidistrict Litigation, including emails, memos and internal presentations centered on whether a research paper would undercut Pradaxa®’s main selling points that regular blood tests are not required with use of Pradaxa®. The article noted that the unsealed internal documents demonstrate that Boehringer Ingelheim employees “openly fretted” when it appeared that the results of the research paper, written by Paul A. Reilly, a clinical program director at the company, indicated that some patients could benefit from monitoring of their blood. Further, the article noted that the newly unsealed documents demonstrate that “[t]he makers of the blood-thinning drug Pradaxa® were so worried that [the] internal research paper would damage drug sales that some employees not only pressured the author to revise it, but suggested it should be quashed altogether.”

And before that on December 9, 2013, the federal court presiding over the Pradaxa® Multidistrict Litigation entered an order sanctioning Boehringer Ingelheim, the manufacturer of Pradaxa®, for continued discovery violations. As stated in his 51-page order, Chief Judge David R. Herndon was “stunned” by Boehringer’s “egregious” discovery violations. The Court further found that Boehringer’s actions were in “bad faith,” and that monetary sanctions were warranted in the amount of $931,500. (In re Pradaxa (Dabigatran Extexilate) Products Liability Litigation, MDL No. 2385, Case No. 12-md-2385)

About Schlichter, Bogard & Denton, LLP Schlichter, Bogard & Denton, LLP is a unique law firm that aggressively represents its clients injured as a result of dangerous pharmaceutical medications and unsafe medical devices, including Pradaxa®. The attorneys at Schlichter, Bogard & Denton, LLP who represent victims harmed by pharmaceutical manufacturers include Roger Denton, Kristine Kraft, Beth Wilkins Flieger, Ashley Brittain Landers, and Tara Rocque. With hard work, creative thinking, and strong trial skills, we have earned an outstanding nationwide reputation by representing thousands of individuals who have suffered serious injuries. If you or a loved one has suffered injuries after using the blood thinning medication Pradaxa®, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.

Schlichter, Bogard & Denton, LLP also welcomes the opportunity to work with other attorneys on these types of cases. Schlichter, Bogard & Denton, LLP is available to either handle these cases or work as co-counsel, so other attorneys with Pradaxa® cases are invited to contact an attorney at the firm to explore this opportunity.

The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.